Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Louisiana: - West Jefferson Medical Center — Marrero, Louisiana
- Ochsner LSU Health Monroe Medical Center — Monroe, Louisiana
- Louisiana State University Health Science Center — New Orleans, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
- LSU Health Sciences Center at Shreveport — Shreveport, Louisiana
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Louisiana: - Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
- Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
- Medical Center of Baton Rouge — Baton Rouge, Louisiana
- Louisiana Hematology Oncology Associates — Baton Rouge, Louisiana
- Ochsner High Grove — Baton Rouge, Louisiana
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Louisiana: - LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
- Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
- Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
- Ochsner Health Center-Summa — Baton Rouge, Louisiana
- Our Lady of the Lake Physicians Group - Medical Oncology — Baton Rouge, Louisiana
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Louisiana: - Ochsner Medical Center Jefferson — New Orleans, Louisiana
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Louisiana: - Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
- University Medical Center New Orleans — New Orleans, Louisiana
- University Medical Center - New Orleans — New Orleans, Louisiana
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Louisiana: - CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0109) — Alexandria, Louisiana
- Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0063) — Monroe, Louisiana
- Louisiana State University Health Sciences Shreveport ( Site 0029) — Shreveport, Louisiana
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in Louisiana: - Care Access-Marrero — Marrero, Louisiana
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Louisiana: - Ochsner Clinic Foundation — Covington, Louisiana
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Louisiana: - Women's Cancer Care — Covington, Louisiana
Phase 1, Phase 2 Recruiting Industry
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Sponsor: AstraZeneca
NCT ID: NCT05123482
Sites in Louisiana: - Research Site — Shreveport, Louisiana
Phase 1 Recruiting Industry
This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor,…
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT06784193
Sites in Louisiana: - University Medical Center - New Orleans — New Orleans, Louisiana
EARLY Phase 1 Recruiting Industry
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in microdose quantiti…
Sponsor: Pure Biologics S.A.
NCT ID: NCT06700070
Sites in Louisiana: - LSU Health Sciences Center — Shreveport, Louisiana
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Louisiana: - LSU Health Baton Rouge-North Clinic — Baton Rouge, Louisiana
- Our Lady of the Lake Physician Group — Baton Rouge, Louisiana
- Our Lady of The Lake — Baton Rouge, Louisiana
- Louisiana Hematology Oncology Associates LLC — Baton Rouge, Louisiana
- Louisiana Hematology Oncology Associates — Baton Rouge, Louisiana
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Louisiana: - Ochsner LSU Health Monroe Medical Center — Monroe, Louisiana
- LSU Health Sciences Center at Shreveport — Shreveport, Louisiana
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Louisiana: - Massive Bio SYNERGY-AI site — New Orleans, Louisiana
Phase 4 Recruiting Industry
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…
Sponsor: AstraZeneca
NCT ID: NCT07357597
Sites in Louisiana: - Research Site — New Orleans, Louisiana
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Louisiana: - Tulane Cancer Center — New Orleans, Louisiana
- Christus Highland/ Boniol — Shreveport, Louisiana